Imatinib Completed Phase 1 Trials for Refractory Malignancy / Tumors, Solid Treatment

IndicationsStatusPurposePhase
CompletedTreatment1
clinicaltrials.gov IdentifierTitleDrugs
NCT00611689Imatinib and PTK787/ZK222584 in Refractory and/or Advanced Solid Tumors